Structure via PubChem · Public domain (PubChem)
bunazosin
Sign in to saveBunazosin (INN) is an α1-adrenergic receptor antagonist. Bunazosin was initially developed to treat benign prostatic hyperplasia (BPH). It has been approved in Japan in a topical form to treat glaucoma. The mechanism of action is a reduction of aqueous outflow through the uveoscleral pathway resulting in lowering the intraocular pressure. It also may act to improve blood flow to the ocular nerve. Systemic Alpha-1 adrenergic receptor antagonists have been implicated in Intraoperative Floppy Iris Syndrome (IFIS). Bunazosin potentially could have the same effect but there has been no research to
Chemical data
- Formula
- C19H27N5O3
- Molecular weight
- 373.4 g/mol
- IUPAC name
- 1-[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-1,4-diazepan-1-yl]butan-1-one
- SMILES
- CCCC(=O)N1CCCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC
- InChIKey
- RHLJLALHBZGAFM-UHFFFAOYSA-N
- XLogP
- 2.2
- Polar surface area
- 93.8 Ų
- H-bond donors
- 1
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
via ChEMBL · EBI
Research
313 papers- Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage.Cardiovascular drug reviews · 2005
- Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review.Arzneimittel-Forschung · 1995
- Topical Application of Bunazosin Hydrochloride Suppresses Myopia Progression With an Increase in Choroidal Blood Perfusion.Investigative ophthalmology & visual science · 2023
- Bunazosin reduces intraocular pressure in rabbits by increasing uveoscleral outflow.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 1998
- [3H]bunazosin, a novel selective radioligand of alpha 1 adrenoceptors in human prostates.The Journal of urology · 1991
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 373.211
Show 4 more facts
- chemical formula
- C₁₉H₂₇N₅O₃
- canonical SMILES
- CCCC(=O)N1CCCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC
- medical condition treated
- arterial hypertension
- Commons category
- Bunazosin
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Bunazosin (INN) is an α1-adrenergic receptor antagonist. Bunazosin was initially developed to treat benign prostatic hyperplasia (BPH). It has been approved in Japan in a topical form to treat glaucoma. The mechanism of action is a reduction of aqueous outflow through the uveoscleral pathway resulting in lowering the intraocular pressure. It also may act to improve blood flow to the ocular nerve. Systemic Alpha-1 adrenergic receptor antagonists have been implicated in Intraoperative Floppy Iris Syndrome (IFIS). Bunazosin potentially could have the same effect but there has been no research to substantiate this as a risk for cataract surgery.
==References==
Excerpted from Wikipedia’s “bunazosin” article, available under the CC BY-SA 4.0 licence.